Thomas DA et al. investigated the role of TGF-β in tumor evasion of immune surveillance and demonstrated that TGF-β attenuated glioma rejection by inhibiting the cellular expression of key effector molecules, such as granzyme B and IFN-γ (Thomas and Massagué, 2005). The gene discussed is TGFB1; the disease is central nervous system cancer.